SRB1 receptor
Showing 1 - 25 of >10,000
Glucagon-like Peptide-1 Receptor Agonists According to Type 2
Recruiting
- Diabetes Mellitus, Type 2
- GLP-1 receptor agonist
-
Bari, ItalyAzienda Ospedaliero-Universitaria Policlinico Bari
Nov 4, 2023
Incidence of Retained Gastric Food on Endoscopy
Not yet recruiting
- Gastric Content Aspiration
- Esophagogastroduodenoscopy
- (no location specified)
May 16, 2023
Muscarinic Receptor Occupancy Trial in New Haven (Scopolamine, [11C]EMO ([11C]LSN3172176))
Not yet recruiting
- Muscarinic Receptor Occupancy
- Scopolamine
- [11C]EMO ([11C]LSN3172176)
-
New Haven, ConnecticutYale University
Aug 31, 2023
Caveolin 1 Deficiency in Response to Glucagon-like Peptide 1
Not yet recruiting
- Overweight and Obesity
- 24-hour ambulatory blood pressure
- Liberal salt diet
- (no location specified)
Oct 4, 2023
Type 2 Diabetes Trial in Lancaster (Exenatide Injection, Saline injection)
Terminated
- Type 2 Diabetes
- Exenatide Injection
- Saline injection
-
Lancaster, PennsylvaniaAmish Research Clinic
Mar 6, 2023
Preoperative Prandial State of Patients Taking Glucagon-Like
Recruiting
- Pulmonary Aspiration
- Gastric ultrasound
-
Houston, TexasThe University of Texas Health Science Center at Houston
Jun 6, 2023
MS Patients Treated With Sphingosine-1-phosphate Receptor
Recruiting
- Multiple Sclerosis
- S1PR analysis on immune cells
-
Bern, SwitzerlandNeurology department
Apr 12, 2023
Glucagon-like Peptide 1 Receptor Agonists and Mental Health
Not yet recruiting
- Diabetes Mellitus
- +2 more
- GLP-1 receptor agonist
- (no location specified)
Aug 4, 2022
Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer Trial (BGB-43395, Fulvestrant, Letrozole)
Not yet recruiting
- Advanced Solid Tumor
- +8 more
- BGB-43395
- +2 more
- (no location specified)
Nov 13, 2023
Diabetes Trial in Nanjing (Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc)
Recruiting
- Diabetes
- Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc
-
Nanjing, ChinaNanjing First Hospital, Nanjing Medical Univesity
Aug 6, 2023
Primary Aldosteronism Trial in Montréal (Renin measurements)
Not yet recruiting
- Primary Aldosteronism
- Renin measurements
-
Montréal, Quebec, CanadaHôpital du Sacré-Coeur de Montréal
Oct 30, 2023
Digestive System Neuroendocrine Tumor G1, Digestive System Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine
Not yet recruiting
- Digestive System Neuroendocrine Tumor G1
- +5 more
- Tumor Debulking
- +5 more
-
Nashville, TennesseeVanderbilt University/Ingram Cancer Center
Aug 23, 2023
Therapeutic Drug Use for CKD Patients
Active, not recruiting
- Chronic Kidney Disease
- angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blocker
-
Jinan, Shandong, ChinaXiao Li,MD
Apr 18, 2023
B-Cell Lymphoma, Large B-cell Lymphoma, DLBCL, Nos Genetic Subtypes Trial in New York (19(T2)28z1xx TRAC T cell)
Recruiting
- B-Cell Lymphoma
- +4 more
- 19(T2)28z1xx TRAC T cell
-
New York, New YorkMemorial Sloan Kettering Cancer Center (All Protocol Activities)
Feb 24, 2023
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Trial (Giredestrant, Fulvestrant, Abemaciclib)
Not yet recruiting
- Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Giredestrant
- +6 more
- (no location specified)
Sep 26, 2023
Breast Cancer, Chemo-induced Nausea and Vomiting Trial in Hanzhou (Aprepitant, Palonosetron, Fosaprepitant)
Not yet recruiting
- Breast Cancer
- Chemotherapy-induced Nausea and Vomiting
- Aprepitant
- +2 more
-
Hanzhou, Zhejiang, Chinathe Second Affiliated Hospital of Zhejiang Univercity School of
Apr 23, 2023
Synovial Sarcoma Trial in Houston (Fludarabine phosphate, NY-ESO-1 TCR/IL-15 NK, Cyclophosphamide)
Not yet recruiting
- Synovial Sarcoma
- Fludarabine phosphate
- +2 more
-
Houston, TexasMD Anderson Cancer Center
Oct 9, 2023
Osteoporosis, Postmenopausal, Diabetes, Type 2 Trial in Jackson (GLP-1 receptor agonist)
Recruiting
- Osteoporosis, Postmenopausal
- Diabetes Mellitus, Type 2
- GLP-1 receptor agonist
-
Jackson, MississippiUniversity of Mississippi Medical Center
Aug 5, 2022
Neuroendocrine Tumor (NET), Colorectal Cancer (CRC) Trial (CHM-2101 CAR-T cells)
Not yet recruiting
- Neuroendocrine Tumor (NET)
- Colorectal Cancer (CRC)
- CHM-2101 CAR-T cells
- (no location specified)
Sep 20, 2023
Myeloma Trial in Houston (Fludarabine phosphate, Cyclophosphamide, NY-ESO-1 TCR/IL-15 NK)
Not yet recruiting
- Myeloma
- Fludarabine phosphate
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Sep 27, 2023
Clinical Phenotypes in Pericarditis: IL-1RA Antibodies and suPAR
Not yet recruiting
- Pericarditis
- IL1RA Antibody Assay
- suPAR Testing
-
Homburg, Germany
- +8 more
Jun 22, 2023
Thyroid Eye Disease Trial (VRDN-001 10 mg/kg Drug:)
Not yet recruiting
- Thyroid Eye Disease
- VRDN-001 10 mg/kg Drug:
- (no location specified)
Sep 7, 2023
Epidermolysis Bullosa Trial in Redwood City (Serlopitant Tablet, Placebo Oral Tablet)
Completed
- Epidermolysis Bullosa
- Serlopitant Tablet
- Placebo Oral Tablet
-
Redwood City, CaliforniaStanford University
Nov 30, 2022